(VIANEWS) – NAVAMEDIC (NAVA.OL), VERALLIA (VRLA.PA), J.MARTINS,SGPS (JMT.LS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NAVAMEDIC (NAVA.OL)
20.7% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 31.69. Meaning, the purchaser of the share is investing kr31.69 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 51.9%, now sitting on 502.65M for the twelve trailing months.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr37.40 at 01:20 EST, way below its 52-week high of kr43.90 and way above its 52-week low of kr31.00.
More news about NAVAMEDIC.
2. VERALLIA (VRLA.PA)
19.7% sales growth and 44.03% return on equity
Verallia Société Anonyme produces and sells glass packaging products for beverages and food industry worldwide. It also provides bottles for still and sparkling wines, spirits, beers, soft drinks, and oils. The company offers jars for baby food, dairy products, jams, honey, spreads, condiments, sauces, and preserves. Verallia Société Anonyme was founded in 1827 and is based in Courbevoie, France.
Earnings Per Share
As for profitability, VERALLIA has a trailing twelve months EPS of €4.08.
PE Ratio
VERALLIA has a trailing twelve months price to earnings ratio of 8.14. Meaning, the purchaser of the share is investing €8.14 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 44.03%.
Moving Average
VERALLIA’s worth is way below its 50-day moving average of €38.15 and below its 200-day moving average of €36.66.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 8, 2023, the estimated forward annual dividend rate is 1.4 and the estimated forward annual dividend yield is 4.57%.
Volume
Today’s last reported volume for VERALLIA is 21978 which is 85.31% below its average volume of 149710.
Yearly Top and Bottom Value
VERALLIA’s stock is valued at €33.20 at 01:20 EST, way under its 52-week high of €44.86 and way higher than its 52-week low of €26.58.
More news about VERALLIA.
3. J.MARTINS,SGPS (JMT.LS)
17.7% sales growth and 28.68% return on equity
Jerónimo Martins, SGPS, S.A. operates in the food distribution and specialized retail sectors in Portugal, Poland, and Colombia. The company operates through Portugal Retail; Portugal Cash & Carry; Poland Retail; Colombia Retail; and Others, Eliminations and Adjustments segments. It operates food stores under the Biedronka name; and a chain of health and beauty stores under the Hebe banner in Poland, as well as food stores under the Ara name in Colombia. The company also operates supermarkets under the Pingo Doce banner; and cash and carry stores under the Recheio name in Portugal. In addition, it operates restaurants under the Pingo Doce name; Bem-Estar pharmacies; petrol stations; and clothing under Code brand. Further, the company operates kiosks and coffee shops under the Jeronymo name; and chocolates and confectionary retail stores under Hussel name. Additionally, the company engages in human resources top management, real estate management and administration, training, and saline brackish waters aquaculture; wholesale of fruit and vegetables; retail management, consultancy, and logistics activities; the purchase and sale of real estate; growing of crops and farming of animals; retail sale of health and beauty products; manufacture of milk and dairy products; and provision of economic and accounting, business portfolio management, financial, and sea passenger water transport services. It is also involved in the trading and distribution of consumer goods; retail and wholesale of non-food products; other business support service activities; and provision of services in the area of wholesale and retail distribution. The company was founded in 1792 and is headquartered in Lisbon, Portugal. Jerónimo Martins, SGPS, S.A. operates as a subsidiary of Sociedade Francisco Manuel Dos Santos, S.G.P.S., S.A.
Earnings Per Share
As for profitability, J.MARTINS,SGPS has a trailing twelve months EPS of €1.16.
PE Ratio
J.MARTINS,SGPS has a trailing twelve months price to earnings ratio of 19.24. Meaning, the purchaser of the share is investing €19.24 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.68%.
Volume
Today’s last reported volume for J.MARTINS,SGPS is 91894 which is 85.29% below its average volume of 625087.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 15, 2023, the estimated forward annual dividend rate is 0.55 and the estimated forward annual dividend yield is 2.32%.
Sales Growth
J.MARTINS,SGPS’s sales growth is 20.1% for the ongoing quarter and 17.7% for the next.
More news about J.MARTINS,SGPS.
4. AKER SOLUTIONS (AKSO.OL)
16.8% sales growth and 17.09% return on equity
Aker Solutions ASA provides solutions, products, systems, and services to the oil and gas industry worldwide. It offers field planning, feasibility, and concept studies; specialist engineering, project management, and procurement services; floater designs, offshore wind, as well as engages in design, delivery, and construction of deep-water risers, oil, and gas production, and receiving and processing facilities. In addition, the company provides offshore fish farming, carbon capture, utilization and storage, hydrogen, and offshore wind solutions. Further, the company designs and constructs jackets for construction services and offers electrification services; and designs and constructs offshore oil and gas production facilities and onshore receiving and processing facilities. Additionally, the company provides subsea production, compression, pump, power distribution, and processing systems, and subsea lifecycle services. Furthermore, the company offers maintenance, modifications, decommissioning, asset integrity management, hook-up, and completion solutions. Aker Solutions ASA was founded in 1841 and is headquartered in Fornebu, Norway.
Earnings Per Share
As for profitability, AKER SOLUTIONS has a trailing twelve months EPS of kr3.41.
PE Ratio
AKER SOLUTIONS has a trailing twelve months price to earnings ratio of 12.53. Meaning, the purchaser of the share is investing kr12.53 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.09%.
Moving Average
AKER SOLUTIONS’s value is higher than its 50-day moving average of kr42.31 and higher than its 200-day moving average of kr39.19.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Apr 14, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 2.01%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 34.4%, now sitting on 48.05B for the twelve trailing months.
More news about AKER SOLUTIONS.
5. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 16.03% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23.1. Meaning, the purchaser of the share is investing kr23.1 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr23.10 at 01:20 EST, below its 52-week high of kr25.10 and way above its 52-week low of kr15.80.
Volume
Today’s last reported volume for VISTIN PHARMA is 945 which is 94.56% below its average volume of 17390.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the present quarter and 6.6% for the next.
More news about VISTIN PHARMA.
6. SEABIRD EXPLORAT (SBX.OL)
5.7% sales growth and 21.51% return on equity
SeaBird Exploration Plc, together with its subsidiaries, provides marine 2D and 3D seismic data for the oil and gas industry in Europe, Africa, the Middle East, North and South America, and the Asia Pacific. It offers 2D seismic; and source vessels that provide conventional undershoot, 4D repeat survey, wide azimuth, push reverse, long-term charter and vessel management, in-house source modelling and environmental decay analysis, and spot charter services. The company was founded in 1996 and is based in Nicosia, Cyprus.
Earnings Per Share
As for profitability, SEABIRD EXPLORAT has a trailing twelve months EPS of kr0.31.
PE Ratio
SEABIRD EXPLORAT has a trailing twelve months price to earnings ratio of 15.48. Meaning, the purchaser of the share is investing kr15.48 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.51%.
Sales Growth
SEABIRD EXPLORAT’s sales growth is negative 12.4% for the present quarter and 5.7% for the next.
Yearly Top and Bottom Value
SEABIRD EXPLORAT’s stock is valued at kr4.80 at 01:20 EST, way under its 52-week high of kr6.00 and way above its 52-week low of kr3.22.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SEABIRD EXPLORAT’s EBITDA is 244.66.
Volume
Today’s last reported volume for SEABIRD EXPLORAT is 123295 which is 42.71% below its average volume of 215216.
More news about SEABIRD EXPLORAT.
